Efficacy and outcomes of bempedoic acid versus placebo in patients with hypercholesterolemia: an updated systematic review and meta-analysis of randomized controlled trials.
| Autor: | Goyal A; Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India., Shah S; Department of Internal Medicine, Maharajgunj Medical Campus, Kathmandu, Nepal., Dahal K; Department of Internal Medicine, Maharajgunj Medical Campus, Kathmandu, Nepal., Changez MIK; Department of Surgery, Quetta Institute of Medical Sciences, Quetta., Tariq MD; Department of Internal Medicine, Foundation University Medical College, Islamabad., Zuhair V; Department of Medicine, Jinnah Sindh Medical University, Karachi., Shamim U; Department of Internal Medicine, Aga Khan University Hospital, Karachi., Abbasi HQ; Department of Internal Medicine, Ayub Medical College, Abbottabad., Shrestha AB; Department of Internal Medicine, M Abdur Rahim Medical College, Dinajpur, Bangladesh., Sah R; Department of Microbiology, Institute of Medicine, Tribhuvan University, Maharajgunj, Nepal.; Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune, Maharashtra, India., Sohail AH; Department of Surgery, University of New Mexico Health Sciences, Albuquerque, New Maxico, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cardiovascular endocrinology & metabolism [Cardiovasc Endocrinol Metab] 2024 Jun 20; Vol. 13 (3), pp. e0302. Date of Electronic Publication: 2024 Jun 20 (Print Publication: 2024). |
| DOI: | 10.1097/XCE.0000000000000302 |
| Abstrakt: | Introduction: Bempedoic acid (BA) has shown varied efficacy in managing hyperlipidemia. We conducted the most extensive up-to-date meta-analysis, the first to include recent studies by Nissen et al., which boast the largest sample size. Methods: Literature search was done on Medline, EMBASE, and Cochrane Library. The primary endpoint was a change in low-density lipoprotein-cholesterol (LDL-C) levels, while secondary endpoints encompassed changes in lipid parameters, clinical endpoints, and safety endpoints. The least-square mean (LSM) percent change was utilized for lipid changes, with statistical significance set at P < 0.05. Results: This analysis included 12 randomized control trials with 22,249 participants. BA exhibited a substantial reduction in LDL-C levels [LSM % change, -24.34; 95% confidence interval (CI), -27.80 to -20.88; P < 0.0001], total cholesterol levels (LSM % change, -16.62; 95% CI, -21.70 to -11.54; P < 0.00001) and high-density lipoprotein-cholesterol (HDL-C) levels (LSM % change, -4.22; 95% CI, -5.51 to -2.92; P < 0.00001) compared to the placebo. Conclusions: BA significantly lowers LDL-C, total cholesterol, HDL-C, non-HDL-C, high sensitivity C reactive protein, and apolipoprotein levels. Competing Interests: There are no conflicts of interest. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|